Rhythm Pharmaceuticals

US · RYTM #1874 by market cap Listed 2017

88.45 -2.32 -2.56%

Live - 5344 symbols - heartbeat 455s ago · 2026-10-08 08:06

Pre-market 87.90 -0.62%

After-hours 88.45 0.00%

Overnight 88.34 -0.12%

Market cap: 6.09B
P/E (TTM): -28.35
P/B: 59.12
EPS: -3.11
Div yield: 0.00%
52W pos: 29%

Reader sentiment Are you bullish or bearish on RYTM?

Anonymous reader poll. Unscientific, not investment advice.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Founded: 2008
CEO: Dr. David P. Meeker,M.D.
Employees: 414
Headquarters: Boston, Massachusetts, United States of America
Fiscal year end: 12-31
Website: rhythmtx.com

Company profile

Exchange: US
Symbol: RYTM
Market-cap rank: #1874
Listing date: 2017-10-05
Market cap: 6.09B
Float cap: 4.96B
Shares out: 68.85M
Float shares: 56.04M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:06:05 · For reference only, not investment advice and not tailored to your situation.